Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia



Status:Completed
Conditions:Schizophrenia
Therapuetic Areas:Psychiatry / Psychology
Healthy:No
Age Range:18 - 65
Updated:10/2/2013
Start Date:September 2011
End Date:March 2016
Contact:Compass Schizophrenia
Email:compass.schizophrenia@quintiles.com

Use our guide to learn which trials are right for you!

A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia


The purpose of this study is to assess the long-term safety, tolerability and efficacy of
oral OPC-34712 as monotherapy in adults with schizophrenia.


Schizophrenia is a severely debilitating mental illness that affects approximately 1% of the
world population. Hallucinations and delusions are the most striking characteristic positive
symptoms of schizophrenia; however, more subtle negative symptoms (eg, social withdrawal and
lack of emotion, energy, and motivation) may also be present. The first antipsychotics
developed for the treatment of schizophrenia were effective against positive symptoms, but
showed little efficacy for negative symptoms and were also associated with a high incidence
of side effects. Second generation antipsychotics, represent a significant advancement in
the treatment of psychotic disorders because they are effective and at the same time exhibit
fewer side effects than first generation antipsychotics. Although generally safer than
first generation antipsychotics, the second-generation antipsychotics are not devoid of
undesirable side effects such as Hyperprolactinemia and weight gain. In addition, the
safety of these drugs vary considerably.

Inclusion Criteria:

1. Male or female subjects between 18 and 65 years of age, with a diagnosis of
schizophrenia, as defined by DSM-IV-TR criteria

2. Outpatient status at last visit of Trial 331-10-230 or Trial 331-10-231

3. Willing to discontinue all prohibitive psychotropic medications to meet protocol
required washouts prior to and during the trial period.

4. Other protocol specific inclusion criteria may apply.

Exclusion Criteria:

1. Females who are breast-feeding and/or who have a positive pregnancy test result prior
to receiving study drug

2. Subjects with a current DSM-IV-TR Axis I diagnosis of:

- Schizoaffective disorder

- MDD

- Bipolar disorder

- Delirium, dementia, amnestic or other cognitive disorder

- Borderline, paranoid, histrionic, schizotypal, schizoid or antisocial
personality disorder

3. Subjects presenting with a first episode of schizophrenia

4. Other protocol specific exclusion criteria may apply.
We found this trial at
17
sites
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
Charleston, South Carolina 29412
?
mi
from
Charleston, SC
Click here to add this to my saved trials
?
mi
from
Chattanooga, TN
Click here to add this to my saved trials
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
?
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
?
mi
from
Fort Smith, AR
Click here to add this to my saved trials
?
mi
from
Jackson, MS
Click here to add this to my saved trials
?
mi
from
Metairie, LA
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Overland Park, KS
Click here to add this to my saved trials
?
mi
from
Park Ridge, IL
Click here to add this to my saved trials
?
mi
from
Santa Clara, CA
Click here to add this to my saved trials
?
mi
from
Seattle, WA
Click here to add this to my saved trials
?
mi
from
St. Joseph, MO
Click here to add this to my saved trials
?
mi
from
Washington,
Click here to add this to my saved trials